Avexitide

CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals has announced the commencement of an underwritten public offering of $350.0 million...

CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals, Inc. announced positive topline results from the Phase 3 LUCIDITY clinical trial...

CAMBRIDGE, Mass., August 17, 2026 Amylyx Pharmaceuticals, Inc. announced that it will report topline results from the Phase 3...

CAMBRIDGE, Mass., August 6, 2026 Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its...

CAMBRIDGE, Mass., United States – May 5, 2026 Amylyx Pharmaceuticals Inc. has announced the launch of a U.S. Expanded...